Heidi Cuthbert

Allurion Technologies (NYSE:ALUR) received U.S. Food and Drug Administration (FDA) premarket approval (PMA) for its Allurion Gastric Balloon System, marking a significant expansion into the U.S. obesity care market.

PVW Resources (ASX:PVW) completed its 100% acquisition of Southern Prospecting, securing its foothold in one of the world’s most renowned mining jurisdictions.

For the period ended Dec. 31, 2025, Symal Group (ASX:SYL) reported normalised revenue of $504.2 million, marking a 20.7% increase a year earlier.

Shares in Pantoro Gold (ASX:PNR) rallied sharply in early Feb. 23 trade after the gold miner unveiled plans for a major capital management initiative.

FBR (ASX:FBR) enters a commercial "inflection point," scaling its Mantis and Hadrian robotic platforms through a dual-engine growth strategy.

Biome (ASX:BIO) has delivered its performance for the first half of FY26, headlined by a net profit of $1.2 million, a 172% increase over the previous year.

Adairs (ASX:ADH) achieved record total sales of $329 million in H1 FY26, marking a 5.9% increase compared to the same period last year.

Aged care giant Regis Healthcare (ASX:REG) reported a sharp 45.1% decline in statutory net profit for the first half of FY26, falling to $13.4 million.

Three days after the Supreme Court torpedoed most of Donald Trump’s global tariffs, markets are still cheering the rollback of his 10% import wall and the curb on presidential emergency powers.

Bayer has filed a lawsuit against Johnson & Johnson (NYSE:JNJ) and its subsidiary Janssen Biotech, alleging the healthcare giant is using "scientifically flawed" and misleading marketing to steal market share for its prostate cancer treatment, Erleada.